Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

July 26, 2017

Study Closes the Debate on Vasectomy- Prostate Cancer Link

Author(s):

Brielle Urciuoli

For years, people believed that there was a link between vasectomies and prostate cancer.

In the 1980s and 1990s, reports were published noting that there may be a connection between vasectomies and prostate cancer. A team of researchers from the Mayo Clinic in Rochester, Minnesota and the University of Toronto sought a clearer answer. In examining much of the available evidence, they determined that getting a vasectomy will not increase a man’s risk of developing prostate cancer.

“With the aim of shedding some light onto a debate that is three decades old, we conducted a systematic review of the literature and performed a meta-analysis, with a particular attention to study quality, to determine if there is an association between vasectomy and prostate cancer,” the researchers wrote in the study.

Results of more than 40 studies were considered — comprising of more than 12 million participants. After eliminating the studies that were at high risk for bias, the researchers found a weak or nonsignificant association between prostate cancer and vasectomies.

The study examined risk of different types of prostate cancer — high-grade prostate cancer, advanced prostate cancer and fatal prostate cancer – and did not find an increased risk for any of them.

“At most, there is a trivial, non-clinically significant association between vasectomy and prostate cancer risk, that is unlikely to be causal,” Bimal Bhindi, M.D., fellow of Urologic Oncology at the Mayo Clinic said in an interview with CURE. “This weak observed association may be due to residual unmeasured confounding in the synthesized studies. Concerns about prostate cancer risk shouldn't prevent men from considering vasectomy as a viable long-term contraceptive option.”

Previous reports suggested that the effects of a vasectomy, such as hormonal imbalances, immunologic effects and cell proliferation changes may play a role in a man’s susceptibility to prostate cancer, however, the authors wrote that the exact mechanisms still have not been proven or understood — even in animal models.

Further, many of the studies in decades prior were observational studies, which are often susceptible to confounding and other limitations.

“Vasectomies are often done by urologists and general practitioners,” Bhindi said. “If men go in to see a GP or urologist, they are more likely to get a PSA test. In turn, if they get screened, they are more likely to have a prostate cancer detected.”

An observational study, therefore, is much more likely to show that more men who get vasectomies get prostate cancer. But does this does not prove that the vasectomy was the cause of the cancer.

Only an estimated 8 to 12 percent of couples use vasectomy as their form of birth control, but the authors on the study urge men not to fear prostate cancer when making that decision.

“This association is unlikely to be causal and should not preclude the use of vasectomy as a long-term contraceptive option,” the study says.

While Bhindi said that he cannot be sure that the low incidence of vasectomy as a birth control method is due to the notion that it might cause cancer, he did note that it could have been a deterring factor for some men.

“When considering male contraceptive options, hearing that vasectomy might cause cancer can be highly dissuading, and may cause men to overlook several of the benefits of vasectomy as an effective and cost-efficient long-term contraceptive option,” he said.

While many studies often leave room for further research, Bhindi actually said that this report ends the debate, once and for all.

“We feel our study synthesizes the literature in a way that hopefully can bring closure to the debate. In the setting of limited research resources, we in fact advised against further research on this topic, as discussed in our paper,” he said.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Tagawa.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of man with brown and grey hair.
Related Content
Advertisement
Photo of a patient in consultation with a doctor.
April 25th 2025

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

Spencer Feldman
Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

Ashley Chan
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man and doctor.
April 12th 2025

NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

Alex Biese
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
Photo of a doctor and patient speaking over a desk
April 9th 2025

PROSTOX May Predict Urinary Side Effects Post Prostate Cancer Radiation

Alex Biese
A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.
Related Content
Advertisement
Photo of a patient in consultation with a doctor.
April 25th 2025

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

Spencer Feldman
Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

Ashley Chan
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man and doctor.
April 12th 2025

NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

Alex Biese
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
Photo of a doctor and patient speaking over a desk
April 9th 2025

PROSTOX May Predict Urinary Side Effects Post Prostate Cancer Radiation

Alex Biese
A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.